


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) Formula (I) compounds



in which

the various R_1 , R_2 , R_3 and R_4 , which can be the same or different, are H, OH, , OMe, NO_2 , F, Cl or Br;


- R_1 - R_2 - can also be together: $-\text{CR}_8=\text{CR}_9-\text{X}-$;

- R_1 - R_2 - can also be together: OCH_2O ;

- R_2 - R_3 - can also be together: OCH_2O ;

- R_3 - R_4 - can also be together: OCH_2O ;


Y is a group selected from



~ : cis o trans

R_5 and R_6 , which can be the same or different, are H or halogen;

Ar is a group selected from:



R_8 , R_9 and R_{10} , which can be the same or different, are H, OH, OPO_3H_2 or $\text{OCH}_2\text{OPO}_3\text{H}_2$ and their disodium salt, OR_{11} , OCH_2O , NH_2 , NHR_{11} , NO_2 , alkyl (C_1 - C_4), C_6H_5 , $\text{C}_5\text{H}_4\text{N}$ or halogen wherein at least one of R_8 , R_9 and R_{10} is OPO_3H_2 or $\text{OCH}_2\text{OPO}_3\text{H}_2$ and their disodium salt;

R_{11} is C_1 - C_4 alkyl or acyl, aminoacids residue;

X is O,

Z is CH,

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

2. (Currently Amended) Compound according to claim 1, selected from the group consisting of:

~~eis-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;~~

~~trans-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-4-ol;~~

~~eis-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;~~

~~trans-4-methoxy-6-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran;~~

~~eis-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol;~~

~~trans-5-[2-(3,4,5-trimethoxy-phenyl)-vinyl]-benzofuran-7-ol~~

disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-phosphate;

~~6[(Z)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~6[(E)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;~~

disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-methoxyphosphate;

~~6[(Z)-2-(3-methoxy-4,5-metilendioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;~~

~~6[(E)-2-(3-methoxy-4,5-methylenedioxy-phenil-1-yl)-vinyl]-1-benzofuran-4-ol;~~

disodium 6[(Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]-1-benzo-furan-4-ol 4-O-methoxyphosphate;

~~eis-5-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-7-ol;~~

~~eis-6-[2-(3,5-dimethoxy-phenyl)-vinyl]-benzofuran-4-ol;~~

their enantiomers, diastereoisomers, the respective mixtures and their pharmaceutically acceptable salts.

3.-4 (Cancelled).

5. (Withdrawn) A method of treating cancers that respond to cytotoxic activity comprising administering to a subject in need of the sale an effective amount of a compound of claim 1.

6. (Withdrawn) The method according to claim 5, in which said cancer is selected from the group consisting of sarcoma, carcinoma, carcinoid, bone cancer, neuroendocrine cancer, lymphoid leukaemia, myeloid leukaemia, monocytic leukaemia, megakaryocytic leukaemia, or Hodgkin's disease.

7. (Withdrawn) A method of treating diseases related to abnormal angiogenesis comprising administering to a subject in need of same an effective amount of a compound of claim 1.


8. (Withdrawn) The method according to claim 7, in which said disease is selected from the group consisting of arthritic disease, tumours responding to antiangiogenic activity, metastatic spread, diabetic retinopathy, psoriasis, chronic inflammation, and atherosclerosis.

9. (Withdrawn) The method according to claim 5, in which, in the treatment of tumours, said compound is combined with at least one other antiproliferative drug.

10. (Withdrawn) The method according to claim 9, in which said antiproliferative drug is selected from the group consisting of alkylating agents; topoisomerase inhibitors; antitubulin agents; intercalating agents; antimetabolites; naturally occurring products such as Vinca alkaloids, epipodophyllotoxins, antibiotics, enzymes, taxanes and anticancer vaccines.

11. (Previously Presented) A pharmaceutical composition containing as the active ingredient a compound according to claim 1 in a mixture with a pharmaceutically acceptable excipient or diluent.


12. (Withdrawn) Use of the compound with the formula



in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claims 1-2.


13. (Withdrawn) Compound with the formula:



in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

14. (Withdrawn) Compound with the formula




in which

X is oxygen or sulphur, R is methyl, or terbutyl-dimethylsilyl.

R₁ is formyl.


15. (Withdrawn) Use of the compound with the formula



in which

X is oxygen or sulphur, as an intermediate product for the preparation of compounds according to claims 1-2.


16. (Withdrawn) Compound with the formula



in which

X is oxygen or sulphur.

17. (Withdrawn) Compound with the formula



in which

X is oxygen or sulphur.

18. (Cancelled)